885-75-6Relevant articles and documents
Asymmetric Transfer Hydrogenation: Dynamic Kinetic Resolution of α-Amino Ketones
Gediya, Shweta K.,Clarkson, Guy J.,Wills, Martin
, p. 11309 - 11330 (2020/10/12)
A series of α-amino ketones were reduced using asymmetric transfer hydrogenation (ATH) through a dynamic kinetic resolution (DKR). The protecting group was matched to the reducing agent, and following optimization, a series of substrates were investigated, giving products in high diastereoselectivity, over 99% ee in several cases and full conversion. The methodology was applied to the enantioselective synthesis of an MDM2-p53 inhibitor precursor.
Concise synthesis of 1H-pyrazin-2-ones and 2-aminopyrazines
Adam, Isabelle,Orain, David,Meier, Peter
, p. 2031 - 2033 (2007/10/03)
Convenient syntheses of 1H-pyrazin-2-ones and 2-aminopyrazines are described. By coupling Boc-protected amino acids with α-amino ketones or with amino alcohols and subsequent oxidation, 1H-pyrazin-2-ones were obtained. Transformation into the corresponding pyrazine triflates and substitution with primary or secondary amines led to 2-aminopyrazines. Since these syntheses take advantage of the use of readily available starting materials (e.g., amino acids, aminoalcohols and amines) a variety of the entitled structures can be obtained in few, high yielding steps.
Pyrrolomorphinans as δ opioid receptor antagonists. The role of steric hindrance in conferring selectivity
Farouz-Grant,Portoghese
, p. 1977 - 1981 (2007/10/03)
A series of 2',3'-disubstituted pyrrolomorphinans (5a-i) were synthesized to determine the role of steric hindrance at μ and γ receptors in promoting δ opioid receptor antagonist selectivity. In smooth muscle preparations, five members of the series (5a-c,e,f) possessed K(e) values in the range 2-15 nM and were 6 selective. Since the unsubstituted analogue 4 possessed δ antagonist potency of similar magnitude, but was not δ selective, it is suggested that the 2',3'substitution confers δ selectivity by hindering the interaction of the pharmacophore at μ and γ receptors, while not affecting δ receptors.